Microbicide Study IPM 020

Every day, more than 3,000 women and girls around the world are infected with HIV.

Women urgently need new prevention options that they can control and use to protect their own health.

What is IPM 020?
IPM 020 is a research study that is testing the safety and acceptability of a new product, called a microbicide, which is being developed to protect women from HIV infection during sex. The microbicide in this study is a vaginal gel that contains the antiretroviral (ARV) drug dapivirine, which is being tested against a placebo gel.

Who can participate?
HIV-negative women, between the ages of 18 and 40, who volunteer for approximately four months after screening. Each woman gives informed consent based on a clear understanding of the risks and benefits involved in study participation.

Who is sponsoring this study?
International Partnership for Microbicides (IPM) is a non-profit product development partnership (PDP) established in 2002 to prevent HIV transmission by accelerating the development and availability of a safe and effective microbicide for use by women in developing countries. IPM is committed to providing women with an affordable and self-initiated HIV- prevention strategy to reduce the cycle of infection which has led to the deaths of more than 25 million people worldwide and orphaned more than 15 million children since 1981.

For more information about IPM, visit: www.ipm-microbicides.org.

To volunteer for our microbicide study in Seattle, call 206.667.2300